The Journal for ImmunoTherapy of Cancer (JITC) welcomes submissions in the following areas and related topics:
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the antitumor immune response, and oncolytic viruses.
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape.
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the state-of-the-art in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
Content freely available upon publication.
Articles published within 2-4 weeks of acceptance.
JITC touts an impact factor of 8.374, which it first received in June 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Featured in six major indexing resources including:
Published by BioMed Central, a member of the Committee on Publishing Ethics.
Monthly JITC Digest sent to global experts and Twitter coverage.
Recipients Receive $1,000* and recognition at SITC's Annual Meeting.
*Papers published between August 2018 to September 2019 authored by SITC members are eligible for nomination for awards. Papers on which the first or senior author is a SITC member are eligible for consideration. Join SITC, renew your membership, or check your current membership status.
Submit your Manuscript to JITC
Hello Anyone can share their experience with sarcoidosis flare after treatment with a PD-1 inhibitor? Thank you ------------------------------ Priscila Goncalves Associate Director Center for Novel Cancer Therapies Northwell Health - Monter Cancer Center ...
The New York Academy of Sciences is proud to present three events this May that we think would be of outstanding interest to the community-- Targeting Tumor Heterogeneity , Cancer Metabolism and Signaling , and Frontiers in Cancer ...
The Geriatrics and Palliative Care Symposium brings practitioners from varying healthcare settings to develop the necessary skills to improve the quality and delivery of geriatrics and palliative care.
Didactic lectures, moderated panels, and ...
i will soon, thank you NOTICE - This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org